---
document_datetime: 2023-09-21 21:25:06
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: evra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.0215556
conversion_datetime: 2025-12-29 22:06:04.37385
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EVRA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0053              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 09/11/2022                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0051/G   | This was an application for a group of variations. Labelling or PL                                                                                                                                                                                                                                                                                                       | 13/06/2022   | 20/10/2022   | SmPC, Labelling and PL   | C.I.3.z - Change(s) in the SPC,   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| IAIN/0050/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - control/testing | 20/09/2021   | 20/10/2022   | Annex II and PL          | Not including batch               |
| II/0048/G   | This was an application for a group of variations. B.II.a.3.b.5 - Changes in the composition (excipients) of the finished product - Other excipients - Change that is supported by a bioequivalence study B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range            | 02/09/2021   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

| T/0049             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/08/2021   | 20/08/2021   | SmPC, Labelling and PL   |                                                                                                                                                                                             |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1311/ 201911 | Periodic Safety Update EU Single assessment - ethinylestradiol / norelgestromin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/07/2020   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                           |
| II/0046/G          | This was an application for a group of variations. Update of section 4.8 of the SmPC in order to add anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency rare, following the update of the company's core data sheet (CCDS) due to new data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/05/2020   | 21/05/2021   | SmPC, Annex II and PL    | Section 4.8 of the SmPC has been updated in order to add anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency rare. The Package Leaflet is updated accordingly |
| IAIN/0045          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/12/2018   | 09/12/2019   | SmPC and PL              |                                                                                                                                                                                             |
| N/0044             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/10/2018   | 09/12/2019   | PL                       |                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IA/0043   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/09/2018   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041   | Update of sections 4.3, 4.4, and 4.5 of the SmPC, in line with the PI wording for a class effect agreed by CMDh, in order to add a contraindication for patients receiving drug combinations with Direct-acting antiviral (DAA) agents that contain paritaprevir/ritonavir, ombitasvir, and/or dasabuvir as these DAAs have the potential for a drug-drug interaction with ethinyl estradiol (EE)-containing combined hormonal contraceptives resulting in ALT elevations. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representative in the Netherlands in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 05/05/2017   | 23/06/2017 | SmPC and PL | During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequent in women using ethinyl estradiol-containing medications such as combined hormonal contraceptives (CHCs). Therefore, EVRA-users must switch to an alternative method of contraception (e.g., progestagen-only contraception or non-hormonal methods) prior to starting therapy with this combination drug regimen. EVRA can be restarted 2 weeks following completion of treatment with this combination drug regimen. |
| IA/0040   | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/06/2016   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0039   | Update of section 4.5 of the SmPC as a result of the CMDh opinion issued in March 2015 on the deletion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/04/2016   | 06/04/2017 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                    | of interaction between broad spectrum antibiotics and combined oral contraceptives. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                   |            |            |             |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| II/0038/G          | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 25/02/2016 | n/a        |             |                                   |
| PSUSA/1311/ 201411 | Periodic Safety Update EU Single assessment - ethinylestradiol / norelgestromin                                                                                                                                                                                                                                                                                                                                                 | 11/06/2015 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0037            | To update the annexes to the latest QRD template (version 9). In addition editorial corrections have been made (i.e. local representatives for BE, BG, CZ, DA, ET, FR, IS, CY, LU, MT, NO, PT, RO, SL and FI, and formatting). C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                   | 10/04/2015 | 30/03/2016 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|          | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                            |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0531  | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                            | 05/03/2015 | n/a        |             |                                                                                                                                                                                                                                            |
| A31/0031 | Pursuant to Article 31 of Directive 2001/83/EC, review of the benefit-risk balance of combined hormonal contraceptives containing chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate at the request of the French medicines agency (ANSM) following concerns about the risk of venous thromboembolism. | 21/11/2013 | 16/01/2014 | SmPC and PL | Please refer to the assessment report: EMEA/H/A- 31/1356/C/410/0031                                                                                                                                                                        |
| IA/0034  | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                   | 18/11/2013 | n/a        |             |                                                                                                                                                                                                                                            |
| IG/0341  | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                | 31/07/2013 | n/a        |             |                                                                                                                                                                                                                                            |
| II/0028  | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                        | 21/02/2013 | 16/01/2014 | SmPC and PL | The SmPC and PIL changes are proposed in section 4.4 Special Warnings and Precautions for Use and section 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction. The package leaflet has been amended accordingly. |

<div style=\"page-break-after: always\"></div>

| IB/0030   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH   | 14/02/2013   | 16/01/2014   | SmPC                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0029 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                               | 21/11/2012   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| R/0027    | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 19/04/2012   | 15/06/2012   | SmPC, Annex II, Labelling and PL | Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of EVRA for female contraception indication remains positive and therefore recommends the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                 |
| II/0026   | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                       | 19/01/2012   | 21/02/2012   | SmPC and PL                      | To update the sections 2, 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.2, 5.3, 6.3, 6.5, 6.6 and 10 of the SmPC in order to comply with the EU Guideline on Summary of Product Characteristics (SmPC) (2009) and the inclusion of safety information to include a warning on smoking and age, add 'increased appetite' (SOC Metabolism and nutrition disorders) with the frequency uncommon and additional information on a drug interaction with etoricoxib. The Package Leaflet has been updated in accordance. |
| IB/0024   | B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                            | 30/07/2010   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0023/G | This was an application for a group of variations.                                                                                                                                                                                                           | 07/04/2010   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.7 - Administrative change - Deletion of manufacturing sites   |            |            |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021 | Change to the supplier and/or plant of two excipients of EVRA transdermal patch. Quality changes                                                                                                                                                      | 17/12/2009 | 06/01/2010 |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0022 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                      | 19/11/2009 | 22/12/2009 | SmPC and PL         | Following a CCDS revision by the MAH, section 4.5 'Interactions' and section 4.8 'undesirable effects' of the SPC have been updated. Section 4.5 has been completely reworded taking into account products of the same class that were reviewed recently. Further, one adverse drug reaction \"abnormal taste\" has been added to section 4.8. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes and to update the list of local representatives in the Package Leaflet. |
| IA/0020 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                                                               | 24/06/2009 | n/a        |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0019 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                  | 24/06/2009 | n/a        |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0018 | The Marketing Authorisation Holder applies to update the expression of the release rate of EVRA patch based on a new study which shows that the average                                                                                               | 20/11/2008 | 22/12/2008 | SmPC, Labelling and |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | release rates of Ethinyl Estradiol and Norelgestromin onto the skin are respectively 33.9 micrograms per day and 203 micrograms per day. There are no changes to the qualitative and quantitative composition of the patch nor any change to its functional characteristics. This amendment is done only to reflect the amount of active substance released from the patch onto the skin instead of the quantity of active substance measured in the systemic blood circulation as previously. Annexes and embossing of the patch are updated accordingly.   |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017 | Update of Summary of Product Characteristics and Package Leaflet Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/07/2008 | 08/09/2008 | SmPC and PL | The hypertension contraindication is further clarified in section 4.3 'Contraindications' of the SPC. Evra is contraindicated in patients with severe hypertension, i.e. with persistent blood pressure values equal or greater of 160 mm Hg for the systolic or equal or greater than 100 mm Hg for the diastolic. Following literature reports referring to a clinical trial as well as the search of the safety database of the MAH, the information of interaction of the combined contraceptives and lamotrigine has been added in section 4.5 'Interactions with Other Medicinal Products and Other Forms of Interaction' of the SPC. Lamotrigine is an anticonvulsant agent. Combined hormonal contraceptives have been shown to significantly decrease plasma concentrations of lamotrigine when co-administered. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        | be necessary. In addition the Adverse Drug Reaction of 'colitis' is added in the section 4.8 of the SPC based on data from the literature and class effect consistent with an ADR in association with norelgestromin/ethinylestradiol transdermal system. Finally the Package Leaflet of the medicinal product is updated following the User Readability Testing performed by the MAH as requested during the Renewal procedure of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016 | Update of section 4.4 of the SPC with regard to venous thromboembolism (VTE) and section 4.8 'Undesirable effects' was also restructured in accordance to the SPC Guideline. In addition, the MAH amended section 4.5 to include the active substance 'bosentan' as a medicinal product potentially interacting with EVRA. The PL has been updated accordingly. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 24/04/2008 | 20/06/2008 | SmPC, Labelling and PL | Following the finalisation of a Boston Collaborative Drug Safety Program (BCDSP) study, the MAH has updated section 4.4 'Special warnings and precautions for use' of the SPC with a warning related to the increased risk of VTE (deep vein thrombosis, pulmonary embolism) with the use of any combined hormonal contraceptive, including EVRA, compared to no use as recommended by the PhVWP and the CHMP. The results of the retrospective cohort analysis suggest, that the incidence rates for overall VTE risk in women who use EVRA are slightly increased in comparison with users of a levonorgestrel-containing Oral Contraceptives. Section 4.8 'Undesirable effects' was also restructured in accordance to the SPC Guideline. In addition, following the assessment of published data, Section 4.5 'Interaction with other medicinal products and other forms of interaction' was amended to include the active substance 'bosentan' as a medicinal product potentially interacting with EVRA. This interaction can result to breakthrough bleeding and |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                                  | hormonal contraceptive failure. The Product Information was also amended in line with the latest QRD template. The PL has been updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0015  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                           | 24/05/2007 | 07/09/2007 | SmPC, Annex II, Labelling and PL | The quality, safety and efficacy of EVRA continue to be adequately and sufficiently demonstrated since the approval of this product. The benefit/risk profile of EVRA remains favourable in the indication for female contraception. The CHMP considers that the benefit-risk balance of EVRA remains positive, but that its safety profile is to be closely monitored in particular with regards to the Thromboembolic events. Based upon the above defined safety issues of EVRA, the CHMP decided that the MAH should continue to submit yearly PSURs. Finally, considering the above, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time. |
| II/0014 | This variation relates to an update of section 5.2 of the Summary of Product Characteristics (SPC) in relation to pharmacokinetic (PK) profiles and parameters between EVRA and an oral contraceptive containing 250 mcg norgestimate and 35 mcg ethinyl estradiol, following CHMP request further to the assessment of the FUM 033. Update of Summary of Product Characteristics | 14/12/2006 | 25/01/2007 | SmPC                             | Further to the assessment of the FUM 33 (a post-approval commitment to study the pharmacokinetic profile of EVRA transdermal patch in comparison with the pharmacokinetic profile of CILEST, a combined oral contraceptive containing 250mg norgestimate (parent drug of norelgestromin) and 35 micrograms ethinylestradiol), the MAH updated the section 5.2 of the SPC in relation to pharmacokinetic (PK) profiles and parameters between EVRA and the oral contraceptive containing 250 mcg norgestimate and 35                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | mcg ethinyl estradiol by including differences of Cmax values, and inter-subject variability (%CV) for the PK parameters between transdermal and oral combined hormonal contraceptives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013 | This variation relates to an update of section 4.4 of the Summary of Product Characteristics (SPC) concerning an increased risk of Venous Thromboembolic Events (VTE) associated with contraceptive transdermal patches in comparison with oral contraceptives containing norgestimate and 35 mcg of estrogen (ethinyl estradiol). The Package Leaflet (PL) has been updated accordingly. In addition, contact details of Bulgaria and Romania local representatives were also included. Update of Summary of Product Characteristics and Package Leaflet | 14/12/2006 | 25/01/2007 | SmPC and PL | Two epidemiological studies have been performed in the US to assess the risk of thromboembolic disorders (venous and arterial thrombosis) in users of ORTHO EVRA (US patch for transdermal administration that contains 750 mcg of ethinyl estradiol combined with 6 mg of norelgestromin as active substances) compared with users of oral contraceptives containing norgestimate and 35 mcg ethinyl estradiol. One study was conducted by the Boston Collaborative Drug Safety program, the other by the i3 Drug Safety. The results of the two US studies have now become available. According to the data available from these studies, is not possible to exclude a higher risk of VTE with EVRA in comparison with other combined hormonal contraceptives. The current available data (section 4.4 of the SPC and section 2 of the PL) have been updated accordingly. |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/07/2006 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0011 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 05/01/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0010 | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/12/2005 | 21/12/2005 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0009 | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/12/2005 | 21/12/2005 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| N/0008   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                               | 14/03/2005   | n/a        | PL                     |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| II/0006  | Quality changes                                                                                                                                                                                                                                                | 23/06/2004   | 29/06/2004 |                        |
| N/0007   | Marketing Authorisation Holder applied for the inclusion of additional local representatives of the Marketing Authorisation Holder for all new Member States. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 28/05/2004   | n/a        | PL                     |
| IB/0005  | IB_20_b_Change in test procedure for an excipient - minor change (biological excipient)                                                                                                                                                                        | 07/04/2004   | n/a        |                        |
| N/0004   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                               | 03/09/2003   | 03/10/2003 | Labelling and PL       |
| I/0003   | 15_Minor changes in manufacture of the medicinal product                                                                                                                                                                                                       | 21/03/2003   | 22/04/2003 | SmPC and PL            |
| II/0001  | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                 | 18/12/2002   | 04/03/2003 | SmPC, Labelling and PL |
| I/0002   | 31_Change in container shape                                                                                                                                                                                                                                   | 18/12/2002   | 17/02/2003 | SmPC, Labelling and PL |